

Freedom of Information Request: Our Reference CTMUHB_410_23

You asked:

I am trying to understand current practice in the treatment of Hidradenitis Suppurativa (HS). Could you please tell me how many patients were treated in the last 3 months for Hidradenitis Suppurativa (HS) with the following biologic drugs:

Adalimumab - Humira

Adalimumab Biosimilar

Bimekizumab

Certolizumab

Infliximab - Remicade

Infliximab Biosimilar

Secukinumab

Ustekinumab

Our response:

We can confirm that the Health Board does not centrally record this information. The information you require would be recorded within an individual patient's health record as part of their ongoing care. To provide you with this information, would require a manual trawl and significantly exceed the 18 hours time and £450 cost limit set out within Section 12 of the Freedom of Information Act.

Our Medicines Management system does not capture the detailed information your require (specific condition). However, to assist you with your request Medicines Management are able to confirm the number of patients treated by the Dermatology Department (for any medical condition).

Please see information provided in the table below. The period relates to the last 3 months available which is 1st June 2023 to 31st August 2023.

Medicine	Number of Patients
Adalimumab - Humira	**
Adalimumab Biosimilar	48
Bimekizumab	16
Certolizumab	6
Infliximab - Remicade	0
Infliximab Biosimilar	5
Secukinumab	5
Ustekinumab	35

Where the figures are less than 5, this has been denoted by **. The exact figures have been withheld due to the low numbers involved.

Where numbers are low we have considered that there is the potential for the individuals to be identified from the information provided, when considered with other information that may also be in the public domain. Also, responses under the Freedom of Information Act are made available to the public at large. The data is classed as personal data as defined under the General Data Protection Regulation (GDPR) and Data Protection Act 2018 and its disclosure would be contrary to the data protection principles and constitute as unfair and unlawful processing in regard to Articles 5, 6, and 9 of GDPR. We are therefore withholding this detail under Section 40(2) of the Freedom of Information Act 2000. This exemption is absolute and therefore there is no requirement to apply the public interest test.